{"transactions":[{"id":695846,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:40:53.000Z","date":"2026-08-03","kind":"sale","planned":false,"acquired":false,"shares":2596,"price":26.37,"value":68456.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.61 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,177 shares acquired on May 20, 2026 under the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":30970,"source":{"system":"sec-edgar","filing":"0001751719-26-000008","document":"form4-08052026_100849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000175171926000008/form4-08052026_100849.xml","form_type":"4"}},{"id":910089,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-11T21:10:18.000Z","date":"2025-09-25","kind":"other","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 25, 2025, as the trustee of the Jacqueline Goldstein Trust dated September 17, 2019 (the \"Trust\"), the Reporting Person distributed all 1,000 shares of the Issuer to the beneficiaries of the Trust, including 334 shares to the Reporting Person.  Also on September 25, 2025, the Reporting Person contributed 334 shares to the Baily Goldstein Living Trust dated March 4, 2014, for which the Reporting Person serves as a trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001751719-26-000006","document":"form5-02112026_090215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000175171926000006/form5-02112026_090215.xml","form_type":"5"}},{"id":929064,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-29T00:15:37.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":216675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":216675,"derivative":{"exercise_price":26.31,"expiration_date":"2036-01-25","underlying":"Common Stock","underlying_shares":216675},"source":{"system":"sec-edgar","filing":"0001751719-26-000003","document":"form4-01292026_120134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000175171926000003/form4-01292026_120134.xml","form_type":"4"}},{"id":1078445,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-01T01:05:12.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":107950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vest on July 29, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."}],"balance_after":107950,"derivative":{"exercise_price":3.95,"expiration_date":"2035-07-28","underlying":"Common Stock","underlying_shares":107950},"source":{"system":"sec-edgar","filing":"0001415889-25-020804","document":"form4-07312025_090708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020804/form4-07312025_090708.xml","form_type":"4"}},{"id":1078444,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-01T01:05:12.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant. 25% of the shares underlying this RSU vest on August 1, 2026, and the remaining shares vest in equal quarterly installments thereafter over the following 12 quarters, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,115 shares acquired on May 20, 2025 under the Issuer's 2024 Employee Stock Purchase Plan."}],"balance_after":29115,"source":{"system":"sec-edgar","filing":"0001415889-25-020804","document":"form4-07312025_090708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925020804/form4-07312025_090708.xml","form_type":"4"}},{"id":1256001,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-20T23:30:07.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vest on February 18, 2026, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":180000,"derivative":{"exercise_price":5.06,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001415889-25-004937","document":"form4-02202025_060203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588925004937/form4-02202025_060203.xml","form_type":"4"}},{"id":1465941,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":53475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":53475,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":53475},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465940,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares underlying this option vest on June 6, 2025, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.33,"expiration_date":"2034-06-05","underlying":"Class A Common Stock","underlying_shares":53475},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465939,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":206074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":206074,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Common Stock","underlying_shares":206074},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465938,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vests in three equal installments, subject to the Issuer's satisfaction of certain performance criteria on each of May 6, 2028, May 6, 2029 and May 6, 2030, and subject to acceleration and the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.2,"expiration_date":"2034-05-05","underlying":"Class A Common Stock","underlying_shares":206074},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465937,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":30642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":30642,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Common Stock","underlying_shares":30642},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465936,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying this option vest on October 9, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-10-08","underlying":"Class A Common Stock","underlying_shares":30642},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465935,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":11978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":11978,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":11978},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465934,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vested on May 22, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2033-06-22","underlying":"Class A Common Stock","underlying_shares":11978},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465933,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":171122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":171122,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":171122},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465932,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":171122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"33% of the shares underlying this option vested on January 27, 2024, and the remaining shares vest in equal monthly installments thereafter over the following 48 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Class A Common Stock","underlying_shares":171122},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465931,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":42780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":42780,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":42780},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465930,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying this option vested on January 27, 2023, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.84,"expiration_date":"2032-01-26","underlying":"Class A Common Stock","underlying_shares":42780},"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465929,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":2994,"ownership":{"direct":false,"nature":"By Family Members"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held directly by family members of Reporting Person residing in his primary residence."}],"balance_after":2994,"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465928,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2994,"ownership":{"direct":false,"nature":"By Family Members"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held directly by family members of Reporting Person residing in his primary residence."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465927,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":213903,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by the Baily Goldstein Living Trust dated March 4, 2014, for which the Reporting Person serves as a trustee."}],"balance_after":213903,"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":1465926,"issuer":{"id":4816,"kind":"organization","name":"ALUMIS INC.","symbol":"ALMS"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2024-07-01T20:38:02.000Z","date":"2024-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":213903,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of voting Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held directly by the Baily Goldstein Living Trust dated March 4, 2014, for which the Reporting Person serves as a trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-018595","document":"form4-07012024_080757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1847367/000141588924018595/form4-07012024_080757.xml","form_type":"4"}},{"id":3021730,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021729,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021728,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":44034,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":11.3549,"expiration_date":"2028-08-23","underlying":"Common Stock","underlying_shares":44034},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021727,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":34677,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":7.2671,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":34677},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021726,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":22017,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.9961,"expiration_date":"2026-03-14","underlying":"Common Stock","underlying_shares":22017},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021725,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":15412,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.9961,"expiration_date":"2025-07-20","underlying":"Common Stock","underlying_shares":15412},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021724,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":8807,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.7236,"expiration_date":"2024-12-25","underlying":"Common Stock","underlying_shares":8807},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021723,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":13210,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":4.7236,"expiration_date":"2024-12-25","underlying":"Common Stock","underlying_shares":13210},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021722,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":12960,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":3.1794,"expiration_date":"2024-06-26","underlying":"Common Stock","underlying_shares":12960},"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3021721,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-09-28T21:08:55.000Z","date":"2020-09-28","kind":"other","acquired":false,"shares":31826,"price":100,"value":3182600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 87 shares acquired under the Employment Stock Purchase Plan on September 25, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-052223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120052223/doc4.xml","form_type":"4"}},{"id":3060462,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":3553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":12960,"derivative":{"exercise_price":3.1794,"expiration_date":"2024-06-26","underlying":"Common Stock","underlying_shares":3553},"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060461,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":2447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":2447},"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060460,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":100,"price":93.34,"value":9334.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":31739,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060459,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":1108,"price":90.9891,"value":100815.9228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $90.85 to $91.49 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":31839,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060458,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":700,"price":89.6757,"value":62772.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $89.55 to $89.74 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":32947,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060457,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":2534,"price":88.4026,"value":224012.1884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $88.12 to $88.78 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":33647,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060456,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":700,"price":86.92,"value":60844.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":36181,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060455,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":858,"price":86.1143,"value":73886.0694,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $85.79 to $86.41 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":36881,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060454,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":3553,"price":3.1794,"value":11296.4082,"ownership":{"direct":true},"balance_after":37739,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3060453,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-08-13T00:01:26.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":2447,"price":2.9977,"value":7335.3719,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 771 shares acquired under the Employment Stock Purchase Plan on May 15, 2020."}],"balance_after":34186,"source":{"system":"sec-edgar","filing":"0001209191-20-046484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120046484/doc4.xml","form_type":"4"}},{"id":3156665,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-09T00:05:05.000Z","date":"2020-05-07","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":2447,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-20-028113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120028113/doc4.xml","form_type":"4"}},{"id":3156664,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-05-09T00:05:05.000Z","date":"2020-05-07","kind":"sale","acquired":false,"shares":2719,"price":60.3925,"value":164207.2075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $60.28 to $60.65 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":30968,"source":{"system":"sec-edgar","filing":"0001209191-20-028113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120028113/doc4.xml","form_type":"4"}},{"id":3156663,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-05-09T00:05:05.000Z","date":"2020-05-07","kind":"sale","acquired":false,"shares":3281,"price":59.9616,"value":196734.0096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $59.275 to $60.27 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":33687,"source":{"system":"sec-edgar","filing":"0001209191-20-028113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120028113/doc4.xml","form_type":"4"}},{"id":3156662,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-05-09T00:05:05.000Z","date":"2020-05-07","kind":"exercise","acquired":true,"shares":6000,"price":2.9977,"value":17986.2,"ownership":{"direct":true},"balance_after":36968,"source":{"system":"sec-edgar","filing":"0001209191-20-028113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120028113/doc4.xml","form_type":"4"}},{"id":3224712,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-05T22:24:22.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":67.31,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-016688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120016688/doc4.xml","form_type":"4"}},{"id":3277267,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-13T00:03:46.000Z","date":"2020-02-10","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":8447,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-20-008997","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120008997/doc4.xml","form_type":"4"}},{"id":3277266,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-02-13T00:03:46.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":5200,"price":71.1113,"value":369778.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $70.77 to $71.28 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":30968,"source":{"system":"sec-edgar","filing":"0001209191-20-008997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120008997/doc4.xml","form_type":"4"}},{"id":3277265,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-02-13T00:03:46.000Z","date":"2020-02-10","kind":"sale","acquired":false,"shares":800,"price":69.5269,"value":55621.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $69.09 to $70.025 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":36168,"source":{"system":"sec-edgar","filing":"0001209191-20-008997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120008997/doc4.xml","form_type":"4"}},{"id":3277264,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-02-13T00:03:46.000Z","date":"2020-02-10","kind":"exercise","acquired":true,"shares":6000,"price":2.9977,"value":17986.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,149 shares acquired under the Employment Stock Purchase Plan on November 15, 2019."}],"balance_after":36968,"source":{"system":"sec-edgar","filing":"0001209191-20-008997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919120008997/doc4.xml","form_type":"4"}},{"id":3376557,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":false,"shares":1075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":14447,"derivative":{"exercise_price":2.9977,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":1075},"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376556,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":false,"shares":1651,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.9076,"expiration_date":"2023-04-17","underlying":"Common Stock","underlying_shares":1651},"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376555,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":false,"shares":6147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.9076,"expiration_date":"2022-07-02","underlying":"Common Stock","underlying_shares":6147},"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376554,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":false,"shares":1127,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.6359,"expiration_date":"2022-02-13","underlying":"Common Stock","underlying_shares":1127},"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376553,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"sale","acquired":false,"shares":10000,"price":32.3914,"value":323914.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $32.00 to $32.89 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":29819,"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376552,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":true,"shares":1075,"price":2.9977,"value":3222.5275,"ownership":{"direct":true},"balance_after":39819,"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376551,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":true,"shares":1651,"price":1.9076,"value":3149.4476,"ownership":{"direct":true},"balance_after":38744,"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376550,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":true,"shares":6147,"price":1.9076,"value":11726.0172,"ownership":{"direct":true},"balance_after":37093,"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3376549,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-11-09T02:01:44.000Z","date":"2019-11-07","kind":"exercise","acquired":true,"shares":1127,"price":0.6359,"value":716.6593,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,792 shares acquired under the Employment Stock Purchase Plan on May 15, 2019."}],"balance_after":30946,"source":{"system":"sec-edgar","filing":"0001209191-19-055897","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119055897/doc4.xml","form_type":"4"}},{"id":3604433,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":26268,"kind":"person","name":"Goldstein David M","position":1,"cik":"0001751719","reported_name":"Goldstein David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-08T22:38:23.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 1, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":35.42,"expiration_date":"2029-02-28","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-018225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1751719/000120919119018225/doc4.xml","form_type":"4"}}]}